Literature DB >> 6091333

In vivo and in vitro models of demyelinating disease. IX. Progression of JHM virus infection in the central nervous system of the rat during overt and asymptomatic phases.

O Sorensen, M B Coulter-Mackie, S Puchalski, S Dales.   

Abstract

JHM virus, when inoculated into neonatal rats, can cause either a rapidly fatal acute encephalomyelitis or, after longer incubation periods, a paralytic disease. The cerebrospinal fluid (CSF) and serum anti-JHM virus IgG concentrations present in rats prior to onset of clinical symptoms or during the acute and paralytic phases of disease were compared. High CSF/serum ratios, indicative of local antibody production in the CNS, were noted only where disease was demonstrable suggesting that local antibody production accompanied the infection but did not prevent the neurological disease. Among animals in which neurologic symptoms had not become manifest, only those with elevated CSF/serum ratios were found to have histological CNS lesions. Immunofluorescent microscopy indicated that viral antigens were present in both glia and neurons. Antigen-positive cells were frequently present in histologically normal CNS tissue, while regions of necrosis were antigen negative. Testing for the presence of viral RNA with JHM cDNA probes revealed that the virus was rapidly disseminated throughout the CNS, presumably establishing centers of infection prior to the development of recognizable tissue damage. Viral RNA was also detected in the CNS following recovery from paralysis and as late as 5 months postinfection, where no disease occurred. These findings indicate that, although infection by JHM virus can spread rapidly throughout the CNS, formation of lesions during chronic disease is a slower process. The current data and previous observations suggest that JHM virus can remain in a latent state for periods of at least several months in rats without apparent neurologic disease despite the absence of any known provirus phase in the replicative strategy of coronaviruses.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6091333      PMCID: PMC7130679          DOI: 10.1016/0042-6822(84)90227-7

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  35 in total

1.  Immunopathology of mouse hepatitis virus type 3 infection. III. Clinical and virologic observation of a persistent viral infection.

Authors:  C L Prévost; J L Virelizier; J M Dupuy
Journal:  J Immunol       Date:  1975-09       Impact factor: 5.422

2.  Corona virus induced subacute demyelinating encephalomyelitis in rats: a morphological analysis.

Authors:  K Nagashima; H Wege; R Meyermann; V ter Meulen
Journal:  Acta Neuropathol       Date:  1978-10-13       Impact factor: 17.088

3.  Protein iodination with solid state lactoperoxidase.

Authors:  G S David; R A Reisfeld
Journal:  Biochemistry       Date:  1974-02-26       Impact factor: 3.162

4.  A membrane-filter technique for the detection of complementary DNA.

Authors:  D T Denhardt
Journal:  Biochem Biophys Res Commun       Date:  1966-06-13       Impact factor: 3.575

5.  In vivo and in vitro models of demyelinating disease: endogenous factors influencing demyelinating disease caused by mouse hepatitis virus in rats and mice.

Authors:  O Sorensen; R Dugre; D Percy; S Dales
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

6.  Mouse beta 2-microglobulin cDNA clones: a screening procedure for cDNA clones corresponding to rare mRNAs.

Authors:  J R Parnes; B Velan; A Felsenfeld; L Ramanathan; U Ferrini; E Appella; J G Seidman
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

7.  Intrathecal synthesis of virus antibodies in multiple sclerosis patients.

Authors:  T Arnadottir; M Reunanen; A Salmi
Journal:  Infect Immun       Date:  1982-11       Impact factor: 3.441

8.  Demyelinating encephalomyelitis induced by a long-term corona virus infection in rats. A preliminary report.

Authors:  K Nagashima; H Wege; R Meyermann; V ter Meulen
Journal:  Acta Neuropathol       Date:  1979-03-15       Impact factor: 17.088

9.  Hydrocephalus in suckling rats infected intracerebrally with mouse hepatitis virus, MHV-A59.

Authors:  N Hirano; N Goto; T Ogawa; K Ono; T Murakami; K Fujiwara
Journal:  Microbiol Immunol       Date:  1980       Impact factor: 1.955

View more
  28 in total

1.  Neuroinvasion by human respiratory coronaviruses.

Authors:  N Arbour; R Day; J Newcombe; P J Talbot
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

2.  In vivo and in vitro models of demyelinating disease: efficiency of virus spread and formation of infectious centers among glial cells is genetically determined by the murine host.

Authors:  G A Wilson; S Dales
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

3.  Acute and persistent infection of human neural cell lines by human coronavirus OC43.

Authors:  N Arbour; G Côté; C Lachance; M Tardieu; N R Cashman; P J Talbot
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

4.  Persistent infection of human oligodendrocytic and neuroglial cell lines by human coronavirus 229E.

Authors:  N Arbour; S Ekandé; G Côté; C Lachance; F Chagnon; M Tardieu; N R Cashman; P J Talbot
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

5.  Infection by coronavirus JHM of rat neurons and oligodendrocyte-type-2 astrocyte lineage cells during distinct developmental stages.

Authors:  J M Pasick; S Dales
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

6.  In vivo and in vitro models of demyelinating disease: JHM virus in the rat central nervous system localized by in situ cDNA hybridization and immunofluorescent microscopy.

Authors:  O Sorensen; S Dales
Journal:  J Virol       Date:  1985-11       Impact factor: 5.103

7.  Persistent infection of cultured cells with mouse hepatitis virus (MHV) results from the epigenetic expression of the MHV receptor.

Authors:  S G Sawicki; J H Lu; K V Holmes
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

Review 8.  Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients.

Authors:  Yassine Yachou; Abdeslem El Idrissi; Vladimir Belapasov; Said Ait Benali
Journal:  Neurol Sci       Date:  2020-07-28       Impact factor: 3.830

Review 9.  Should we expect neurological symptoms in the SARS-CoV-2 epidemic?

Authors:  J Matías-Guiu; U Gomez-Pinedo; P Montero-Escribano; P Gomez-Iglesias; J Porta-Etessam; J A Matias-Guiu
Journal:  Neurologia (Engl Ed)       Date:  2020-04-06

Review 10.  Why do SARS-CoV-2 NSPs rush to the ER?

Authors:  Maryline Santerre; Sterling P Arjona; Charles Ns Allen; Natalia Shcherbik; Bassel E Sawaya
Journal:  J Neurol       Date:  2020-09-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.